| Prostate Cancer
Updated: 03/28/2005
References
1. Thomas, L. The Lives of a Cell, Second Edition 1978. New York: Penguin
Books.
2. Bastacky, S.I., Wojno, K.J., Walsh, P.C. et al. Pathological features
of hereditary prostate cancer. J. Urol. 1995; 153: 987–92.
3. Carter, B.S., Bova, G.S., Beaty, T.H. et al. Hereditary prostate
cancer: epidemiologic and clinical features. J. Urol. 1993; 150: 797–802.
4. Heisey, R.E., Carroll, J.C., Warner, E. et al. Hereditary breast
cancer. Identifying and managing BRCA1 and BRCA2 carriers. Can. Fam.
Physician 1999; 45: 114–24.
5. Carter, B.S., Steinberg, G.D., Beaty, T.H. et al. Familial risk
factors for prostate cancer. Cancer Surv. 1991; 11: 5–13.
6. Carter, B.S., Beaty, T.H., Steinberg, G.D. et al. Mendelian inheritance
of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1992; 89:
3367–71.
7. McWhorter, W.P., Hernandez, A.D., Meikle, A.W. et al. A screening
study of prostate cancer in high risk families. J. Urol. 1992; 148:
826–8.
8. Miesfeldt, S., Jones, S.M., Cohn, W. et al. Men's attitudes regarding
genetic testing for hereditary prostate cancer risk. Urology 2000;
55: 46–50.
9. Royal, C., Baffoe-Bonnie, A., Kittles, R. et al. Recruitment experience
in the first phase of the African American Hereditary Prostate Cancer
(AAHPC) study. Ann. Epidemiol. 2000; 10: S68–S77.
10. Sellers, T.A., Potters, L., Rich, S.S. et al. Familial clustering
of cancers of the breast and prostate in a population-based sample
of postmenopausal women. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1994;
35: A1724.
11. Liede, A., Metcalfe, K., Hanna, D. et al. Evaluation of the needs
of male carriers of mutations in BRCA1 or BRCA2 who have undergone
genetic counseling. Am. J. Hum. Genet. 2000; 67: 1494–1504.
12. Fasouliotis, S.J., Schenker, J.G. BRCA1 and BRCA2 gene mutations:
decision-making dilemmas concerning testing and management. Obstet.
Gynecol. Surv. 2000; 55: 373–84.
13. Heinig, J., Jackisch, C., Rody, A. et al. Clinical management of
breast cancer in males: a report of four cases. Eur. J. Obstet. Gynecol.
Reprod. Biol. 2002; 102: 67–73.
14. Gann, P.H., Ma, J., Giovannucci, E. et al. Lower prostate cancer
risk in men with elevated plasma lycopene levels: results of a prospective
analysis. Cancer Res. 1999; 59: 1225–30.
15. Giovannucci, E., Ascherio, A., Rimm, E.B. et al. Intake of carotenoids
and retinol in relation to risk of prostate cancer. J. Natl. Cancer
Inst. 1995; 87: 1767–76.
16. Gerster, H. The potential role of lycopene for human health. J.
Am. Coll. Nutr. 1997; 16: 109–26.
17. Agarwal, S., Rao, A.V. Tomato lycopene and its role in human health
and chronic diseases. CMAJ 2000; 163: 739–44.
18. Heber, D., Lu, Q.Y. Overview of mechanisms of action of lycopene.
Exp. Biol. Med. 2002; 227: 920–3.
19. Arab, L., Steck, S. Lycopene and cardiovascular disease. Am. J.
Clin. Nutr. 2000; 71: 1691S–1695S; discussion, 1696S–1697S.
20. Bosetti, C., Tzonou, A., Lagiou, P. et al. Fraction of prostate
cancer incidence attributed to diet in Athens, Greece. Eur. J. Cancer
Prev. 2000; 9: 119–23.
21. Clinton, S.K., Emenhiser, C., Schwartz, S.J. et al. cis-trans lycopene
isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol.
Biomarkers Prev. 1996; 5: 823–33.
22. van Breemen, R.B., Xu, X., Viana, M.A. et al. Liquid chromatography-mass
spectrometry of cis- and all-trans-lycopene in human serum and prostate
tissue after dietary supplementation with tomato sauce. J. Agric. Food
Chem. 2002; 50: 2214–9.
23. Giovannucci, E. Tomatoes, tomato-based products, lycopene, and
cancer: review of the epidemiologic literature. J. Natl. Cancer Inst.
1999; 91: 317–31.
24. Lu, Q.Y., Hung, J.C., Heber, D. et al. Inverse associations between
plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol.
Biomarkers Prev. 2001; 10: 749–56.
25. Giovannucci, E. A review of epidemiologic studies of tomatoes,
lycopene, and prostate cancer. Exp. Biol. Med. 2002; 227: 852–9.
26. Giovannucci, E., Rimm, E.B., Liu, Y. et al. A prospective study
of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer
Inst. 2002; 94: 391–8.
27. Blumenfeld, A.J., Fleshner, N., Casselman, B. et al. Nutritional
aspects of prostate cancer: a review. Can. J. Urol. 2000; 7: 927–35;
discussion, 936.
28. Mucci, L.A., Tamimi, R., Lagiou, P. et al. Are dietary influences
on the risk of prostate cancer mediated through the insulin-like growth
factor system? BJU Int. 2001; 87: 814–20.
29. Signorello, L.B., Kuper, H., Lagiou, P. et al. Lifestyle factors
and insulin-like growth factor 1 levels among elderly men. Eur. J.
Cancer. Prev. 2000; 9: 173–8.
30. Wang, Y., Corr, J.G., Thaler, H.T. et al. Decreased growth of established
human prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl.
Cancer Inst. 1995; 87: 1456–62.
31. Mukherjee, P., Sotnikov, A.V., Mangian, H.J. et al. Energy intake
and prostate tumor growth, angiogenesis, and vascular endothelial growth
factor expression. J. Natl. Cancer Inst. 1999; 91: 512–23.
32. Chan, J.M., Stampfer, M.J., Giovannucci, E. et al. Plasma insulin-like
growth factor-I and prostate cancer risk: a prospective study. Science
1998; 279: 563–6.
33. Cohen, P., Peehl, D.M., Lamson, G. et al. Insulin-like growth factors
(IGFs), IGF receptors, and IGF-binding proteins in primary cultures
of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991; 73:
401–7.
34. Nakao-Hayashi, J., Ito, H., Kanayasu, T. et al. Stimulatory effects
of insulin and insulin-like growth factor I on migration and tube formation
by vascular endothelial cells. Atherosclerosis 1992; 92: 141–9.
35. Huynh, H., Seyam, R.M., Brock, G.B. Reduction of ventral prostate
weight by finasteride is associated with suppression of insulin-like
growth factor I (IGF-I) and IGF-I receptor genes and with an increase
in IGF binding protein 3. Cancer Res. 1998; 58: 215–8.
36. Miyake, H., Hara, I., Yamanaka, K. et al. Elevation of serum levels
of urokinase-type plasminogen activator and its receptor is associated
with disease progression and prognosis in patients with prostate cancer.
Prostate 1999; 39: 123–9.
37. du Toit, P.J., van Aswegen, C.H., du Plessis, D.J. The effect of
essential fatty acids on growth and urokinase-type plasminogen activator
production in human prostate DU-145 cells. Prostaglandins Leukot. Essent.
Fatty Acids 1996; 55: 173–7.
38. Sears, B. The Omega Rx Zone: The Miracle of High-Dose Fish Oil,
First Edition 2002. New York: HarperCollins.
39. Nie, D., Che, M., Grignon, D. et al. Role of eicosanoids in prostate
cancer progression. Cancer Metastasis Rev. 2001; 20: 195–206.
40. Xu, X.C. COX-2 inhibitors in cancer treatment and prevention, a
recent development. Anticancer Drugs 2002; 13: 127–37.
41. Gupta,S., Srivastava, M., Ahmad, N. et al. Lipoxygenase-5 is overexpressed
in prostate adenocarcinoma. Cancer 2001; 91: 737–43.
42. Fujita, H., Koshida, K., Keller, E.T. et al. Cyclooxygenase-2 promotes
prostate cancer progression. Prostate 2002; 53: 232–40.
43. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T. et al. Inhibitors
of prostaglandin synthesis inhibit human prostate tumor cell invasiveness
and reduce the release of matrix metalloproteinases. Cancer Res. 2000;
60: 4629–37.
44. Kirschenbaum, A., Liu, X., Yao, S. et al. The role of cyclooxygenase-2
in prostate cancer. Urology 2001; 58: 127–31.
45. Tjandrawinata, R.R., Dahiya, R., Hughes-Fulford, M. Induction of
cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma
cells. Br. J. Cancer 1997; 75: 1111–8.
46. Ghosh, J., Myers, C.E. Inhibition of arachidonate 5-lipoxygenase
triggers massive apoptosis in human prostate cancer cells. Proc. Natl.
Acad. Sci. U.S.A. 1998; 95: 13182–7.
47. Ghosh, J., Myers, C.E. Arachidonic acid stimulates prostate cancer
cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res.
Commun. 1997; 235: 418–23.
48. Ghosh, J., Myers, C.E., Jr. Arachidonic acid metabolism and cancer
of the prostate. Nutrition 1998; 14: 48–9.
49. Myers, C.E., Ghosh, J. Lipoxygenase inhibition in prostate cancer.
Eur. Urol. 1999; 35: 395–8.
50. Barham, J.B., Edens, M.B., Fonteh, A.N. et al. Addition of eicosapentaenoic
acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic
acid accumulation in humans. J. Nutr. 2000; 130: 1925–31.
51. Carollo, M., Parente, L., D'Alessandro, N. Dexamethasone-induced
cytotoxic activity and drug resistance effects in androgen-independent
prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol. Res.
1998; 10: 245–54.
52. Harvei, S., Bjerve, K.S., Tretli, S. et al. Prediagnostic level
of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids
and the risk of prostate cancer. Int. J. Cancer 1997; 71: 545–51.
53. Brooks, J.D., Metter, E.J., Chan, D.W. et al. Plasma selenium level
before diagnosis and the risk of prostate cancer development. J. Urol.
2001; 166: 2034–8.
54. Duffield-Lillico, A.J., Reid, M.E., Turnbull, B.W. et al. Baseline
characteristics and the effect of selenium supplementation on cancer
incidence in a randomized clinical trial: a summary report of the Nutritional
Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 2002;
11: 630–9.
55. Clark, L.C., Combs, G.F., Jr., Turnbull, B.W. et al. Effects of
selenium supplementation for cancer prevention in patients with carcinoma
of the skin. A randomized controlled trial. Nutritional Prevention
of Cancer Study Group. JAMA 1996; 276: 1957–63.
56. Venkateswaran, V., Klotz, L.H., Fleshner, N.E. Selenium modulation
of cell proliferation and cell cycle biomarkers in human prostate carcinoma
cell lines. Cancer Res. 2002; 62: 2540–5.
57. Vadgama, J.V., Wu, Y., Shen, D. et al. Effect of selenium in combination
with Adriamycin or Taxol on several different cancer cells. Anticancer
Res. 2000; 20: 1391–1414.
58. Helzlsouer, K.J., Huang, H.Y., Alberg, A.J. et al. Association
between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent
prostate cancer. J. Natl. Cancer Inst. 2000; 92: 2018–23.
59. Zhang, Y., Ni, J., Messing, E.M. et al. Vitamin E succinate inhibits
the function of androgen receptor and the expression of prostate-specific
antigen in prostate cancer cells. Proc. Natl. Acad. Sci. 2002; 99:
7408–13.
60. Heinonen, O.P., Albanes, D., Virtamo, J. et al. Prostate cancer
and supplementation with alpha-tocopherol and beta-carotene: incidence
and mortality in a controlled trial. J. Natl. Cancer Inst. 1998; 90:
440–6.
61. Chan, J.M., Stampfer, M.J., Ma, J. et al. Supplemental vitamin
E intake and prostate cancer risk in a large cohort of men in the United
States. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 893–9.
62. Hirayama, T. A large scale cohort study on cancer risks by diet—with
special reference to the risk reducing effects of green-yellow vegetable
consumption. Princess Takamatsu Symp. 1985; 16: 41–53.
63. Woodson, K., Triantos, S., Hartman, T. et al. Long-term alpha-tocopherol
supplementation is associated with lower serum vascular endothelial
growth factor levels. Anticancer Res. 2002; 22: 375–8.
64. Fleshner, N., Fair, W.R., Huryk, R. et al. Vitamin E inhibits the
high-fat diet promoted growth of established human prostate LNCaP tumors
in nude mice. J. Urol. 1999; 161: 1651–4.
65. Chan, J.M., Giovannucci, E., Andersson, S.O. et al. Dairy products,
calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden).
Cancer Causes Control 1998; 9: 559–66.
66. Chan, J.M., Stampfer, M.J., Ma, J. et al. Dairy products, calcium,
and prostate cancer risk in the Physicians' Health Study. Am. J. Clin.
Nutr. 2001; 74: 549–54.
67. Giovannucci, E., Rimm, E.B., Wolk, A. et al. Calcium and fructose
intake in relation to risk of prostate cancer. Cancer Res. 1998; 58:
442–7.
68. Stacewicz-Sapuntzakis, M., Bowen, P.E., Hussain, E.A. et al. Chemical
composition and potential health effects of prunes: a functional food?
Crit. Rev. Food. Sci. Nutr. 2001; 41: 251–86.
69. Patterson, R.E., Neuhouser, M.L., White, E. et al. Cancer-related
behavior of vitamin supplement users. Cancer Epidemiol. Biomarkers
Prev. 1998; 7: 79–81.
70. Rowling, J.K., Harry Potter and the Goblet of Fire, First Edition
2000, p. 723. New York: Scholastic Press.
71. Peck, S.M. A World Waiting to Be Born. Civility Rediscovered, Second
Edition 1997, p. 50. New York: Bantam Books.
72. Gao, X., Mohideen, N., Flanigan, R.C. et al. The extent of biopsy
involvement as an independent predictor of extraprostatic extension
and surgical margin status in low risk prostate cancer: implications
for treatment selection. J. Urol. 2000; 164: 1982–6.
73. Narayan, P., Gajendran, V., Taylor, S.P. et al. The role of transrectal
ultrasound-guided biopsy-based staging, preoperative serum prostate-specific
antigen, and biopsy Gleason score in prediction of final pathologic
diagnosis in prostate cancer. Urology 1995; 46: 205–12.
74. Moul, J.W., Connelly, R.R., Perahia, B. et al. The contemporary
value of pretreatment prostatic acid phosphatase to predict pathological
stage and recurrence in radical prostatectomy cases. J. Urol. 1998;
159: 935–40.
75. Dattoli, M., Wallner, K., True, L. et al. Prognostic role of serum
prostatic acid phosphatase for 103Pd-based radiation for prostatic
carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 45: 853–6.
76. D'Amico, A.V., Schultz, D., Silver, B. et al. The clinical utility
of the percent of positive prostate biopsies in predicting biochemical
outcome following external-beam radiation therapy for patients with
clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol.
Phys. 2001; 49: 679–84.
77. Haese, A., Graefen, M., Noldus, J. et al. Prostatic volume and
ratio of free-to-total prostate specific antigen in patients with prostatic
cancer or benign prostatic hyperplasia. J. Urol. 1997; 158: 2188–92.
78. D'Amico, A.V., Propert, K.J. Prostate cancer volume adds significantly
to prostate-specific antigen in the prediction of early biochemical
failure after external beam radiation therapy. Int. J. Radiat. Oncol.
Biol. Phys. 1996; 35: 273–9.
79. D'Amico, A.V., Whittington, R., Malkowicz, S.B. et al. A prostate
gland volume of more than 75 cm3 predicts for a favorable outcome after
radical prostatectomy for localized prostate cancer. Urology 1998;
52: 631–6.
80. Feneley, M.R., Landis, P., Simon, I. et al. Today men with prostate
cancer have larger prostates. Urology 2000; 56: 839–42.
81. Kaminski, J.M., Hanlon, A.L., Horwitz, E.M. et al. Relationship
between prostate volume, prostate-specific antigen nadir, and biochemical
control. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 888–92.
82. Thomas, M.D., Cormack, R., Tempany, C.M. et al. Identifying the
predictors of acute urinary retention following magnetic-resonance-guided
prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47:
905–8.
83. Rukstalis, D.B., Goldknopf, J.L., Crowley, E.M. et al. Prostate
cryoablation: a scientific rationale for future modifications. Urology
2002; 60: 19–25.
84. Merrick, G.S., Butler, W.M., Lief, J.H. et al. Temporal resolution
of urinary morbidity following prostate brachytherapy. Int. J. Radiat.
Oncol. Biol. Phys. 2000; 47: 121–8.
85. Merrick, G.S., Butler, W.M., Galbreath, R.W. et al. Relationship
between the transition zone index of the prostate gland and urinary
morbidity after brachytherapy. Urology 2001; 57: 524–9.
86. Steele, G.S., Sullivan, M.P., Sleep, D.J. et al. Combination of
symptom score, flow rate and prostate volume for predicting bladder
outflow obstruction in men with lower urinary tract symptoms. J. Urol.
2000; 164: 344–8.
87. Wang, H., Wallner, K., Sutlief, S. et al. Transperineal brachytherapy
in patients with large prostate glands. Int. J. Cancer 2000; 90: 199–205.
88. Daniell, H.W. Osteoporosis due to androgen deprivation therapy
in men with prostate cancer. Urology 2001; 58: 101–7.
89. Neugut, A.I., Rosenberg, D.J., Ahsan, H. et al. Association between
coronary heart disease and cancers of the breast, prostate, and colon.
Cancer Epidemiol. Biomarkers Prev. 1998; 7: 869–73.
90. Johnstone, P.A., Powell, C.R., Riffenburgh, R. et al. Second primary
malignancies in T1-3N0 prostate cancer patients treated with radiation
therapy with 10-year followup. J. Urol. 1998; 159: 946–9.
91. Vollmer, R.T., Egawa, S., Kuwao, S. et al. The dynamics of prostate
specific antigen during watchful waiting of prostate carcinoma: a study
of 94 Japanese men. Cancer 2002; 94: 1692–8.
92. Arai, Y., Egawa, S., Kuwao, S. et al. The role of volume-weighted
mean nuclear volume in predicting tumour biology and clinical behaviour
in patients with prostate cancer undergoing watchful waiting. BJU Int.
2001; 88: 909–14.
93. Borre, M., Offersen, B.V., Nerstrom, B. et al. Microvessel density
predicts survival in prostate cancer patients subjected to watchful
waiting. Br. J. Cancer 1998; 78: 940–4.
94. Borre, M., Stausbol-Gron, B., Overgaard, J. p53 accumulation associated
with bcl-2, the proliferation marker MIB-1 and survival in patients
with prostate cancer subjected to watchful waiting. J. Urol. 2000;
164: 716–21.
95. Borre, M., Nerstrom, B., Overgaard, J. Association between immunohistochemical
expression of vascular endothelial growth factor (VEGF), VEGF-expressing
neuroendocrine-differentiated tumor cells, and outcome in prostate
cancer patients subjected to watchful waiting. Clin. Cancer Res. 2000;
6: 1882–90.
96. Choo, R., Klotz, L., Danjoux, C. et al. Feasibility study: watchful
waiting for localized low to intermediate grade prostate carcinoma
with selective delayed intervention based on prostate specific antigen,
histological and/or clinical progression. J. Urol. 2002; 167: 1664–9.
97. McLaren, D.B., McKenzie, M., Duncan, G. et al. Watchful waiting
or watchful progression? Prostate specific antigen doubling times and
clinical behavior in patients with early untreated prostate carcinoma.
Cancer 1998; 82: 342–8.
98. Begg, C.B., Riedel, E.R., Bach, P.B. et al. Variations in morbidity
after radical prostatectomy. N. Engl. J. Med. 2002; 346: 1138–44.
99. Noldus, J., Michl, U., Graefen, M. et al. Nerve-sparing radical
retropubic prostatectomy. Results of a patient survey. Urologe A 2001;
40: 102–6.
100. Keetch, D.W., McMurtry, J.M., Smith, D.S. et al. Prostate specific
antigen density versus prostate specific antigen slope as predictors
of prostate cancer in men with initially negative prostatic biopsies.
J. Urol. 1996; 156: 428–31.
101. Maeda, H., Arai, Y., Okubo, K. et al. Value of the free to total
prostate specific antigen ratio and prostate specific antigen density
for detecting prostate cancer in Japanese patients. Int. J. Urol. 1998;
5: 343–8.
102. Chakrabarti, S., Raha, K., Bhunia, C.L. et al. The usefulness
of prostate specific antigen density as a screening method for prostatic
carcinoma. J. Indian Med. Assoc. 2001; 99: 627–8, 630.
103. Oesterling, J.E., Brendler, C.B., Epstein, J.I. et al. Correlation
of clinical stage, serum prostatic acid phosphatase and preoperative
Gleason grade with final pathological stage in 275 patients with clinically
localized adenocarcinoma of the prostate. J. Urol. 1987; 138: 92–8.
104. Partin, A.W., Yoo, J., Carter, H.B. et al. The use of prostate
specific antigen, clinical stage and Gleason score to predict pathological
stage in men with localized prostate cancer. J. Urol. 1993; 150: 110–4.
105. McNeal, J.E. The zonal anatomy of the prostate. Prostate 1981;
2: 35–49.
106. Lee, F., Torp-Pedersen, S.T., Siders, D.B. et al. The use of transrectal
ultrasound in the study of normal and abnormal anatomy of the prostate
gland. In Early Stage Prostate Cancer: Diagnosis and Choice of Therapy,
First Edition, 1989, pp. 23–36. Labrie, F., Dupont, A., Lee, F., Eds.
Amsterdam: Elsevier Science.
107. Djavan, B., Remzi, M., Zlotta, A.R. et al. Combination and multivariate
analysis of PSA-based parameters for prostate cancer prediction. Tech.
Urol. 1999; 5: 71–6.
108. Djavan, B., Zlotta, A., Kratzik, C. et al. PSA, PSA density, PSA
density of transition zone, free/total PSA ratio, and PSA velocity
for early detection of prostate cancer in men with serum PSA 2.5 to
4.0 ng/mL. Urology 1999; 54: 517–22.
109. Djavan, B., Zlotta, A.R., Remzi, M. et al. Total and transition
zone prostate volume and age: how do they affect the utility of PSA-based
diagnostic parameters for early prostate cancer detection? Urology
1999; 54: 846–52.
110. Carter, H.B., Pearson, J.D. Prostate-specific antigen velocity
and repeated measures of prostate-specific antigen. Urol. Clin. North
Am. 1997; 24: 333–8.
111. Barak, M., Cohen, M., Mecz, Y. et al. The additional value of
free prostate specific antigen to the battery of age-dependent prostate-specific
antigen, prostate-specific antigen density and velocity. Eur. J. Clin.
Chem. Clin. Biochem. 1997; 35: 475–81.
112. Vollmer, R.T., Dawson, N.A., Vogelzang, N.J. The dynamics of prostate
specific antigen in hormone refractory prostate carcinoma: an analysis
of cancer and leukemia group B study 9181 of megestrol acetate. Cancer
1998; 83: 1989–94.
113. Carter, H.B., Pearson, J.D., Waclawiw, Z. et al. Prostate-specific
antigen variability in men without prostate cancer: effect of sampling
interval on prostate-specific antigen velocity. Urology 1995; 45: 591–6.
114. Kadmon, D., Weinberg, A.D., Williams, R.H. et al. Pitfalls in
interpreting prostate specific antigen velocity. J. Urol. 1996; 155:
1655–7.
115. Carter, H.B., Pearson, J.D. PSA velocity for the diagnosis of
early prostate cancer. A new concept. Urol. Clin. North Am. 1993; 20:
665–70.
116. Egawa, S., Suyama, K., Takashima, R. et al. Prospective evaluation
of prostate cancer detection by prostate-specific antigen-related parameters.
Int. J. Urol. 1999; 6: 493–501.
117. Hanks, G.E., Hanlon, A.L., Lee, W.R. et al. Pretreatment prostate-specific
antigen doubling times: clinical utility of this predictor of prostate
cancer behavior. Int. J. Radiat. Oncol. Biol. Phys. 1996; 34: 549–53.
118. Stephenson, A.J., Aprikian, A.G., Souhami, L. et al. Utility of
PSA doubling time in follow-up of untreated patients with localized
prostate cancer. Urology 2002; 59: 652–6.
119. Fowler, J.E., Jr., Pandey, P., Seaver, L.E. et al. Prostate specific
antigen regression and progression after androgen deprivation for localized
and metastatic prostate cancer. J. Urol. 1995; 153: 1860–5.
120. Pollack, A., Zagars, G.K., el-Naggar, A.K. et al. Relationship
of tumor DNA-ploidy to serum prostate-specific antigen doubling time
after radiotherapy for prostate cancer. Urology 1994; 44: 711–8.
121. Hanlon, A.L., Diratzouian, H., Hanks, G.E. Posttreatment prostate-specific
antigen nadir highly predictive of distant failure and death from prostate
cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002 Jun 1; 53(2): 297–303.
122. Lee, W.R., Hanks, G.E., Hanlon, A. Increasing prostate-specific
antigen profile following definitive radiation therapy for localized
prostate cancer: clinical observations. J. Clin. Oncol. 1997; 15: 230–8.
123. Roberts, S.G., Blute, M.L., Bergstralh, E.J. et al. PSA doubling
time as a predictor of clinical progression after biochemical failure
following radical prostatectomy for prostate cancer. Mayo Clin. Proc.
2001; 76: 576–81.
124. Zagars, G.K., Pollack, A. Kinetics of serum prostate-specific
antigen after external beam radiation for clinically localized prostate
cancer. Radiother. Oncol. 1997; 44: 213–21.
125. Tarle, M., Frkovic-Grazio, S., Kraljic, I. et al. A more objective
staging of advanced prostate cancer—routine recognition of malignant
endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Prostate 1994; 24: 143–8.
126. Tarle, M., Rados, N. Investigation on serum neurone-specific enolase
in prostate cancer diagnosis and monitoring: comparative study of a
multiple tumor marker assay. Prostate 1991; 19: 23–33.
127. Aihara, M., Lebovitz, R.M., Wheeler, T.M. et al. Prostate specific
antigen and Gleason grade: an immunohistochemical study of prostate
cancer. J. Urol. 1994; 151: 1558–64.
128. Bidart, J.M., Thuillier, F., Augereau, C. et al. Kinetics of serum
tumor marker concentrations and usefulness in clinical monitoring.
Clin. Chem. 1999; 45: 1695–1707.
129. Oremek, G.M., Seiffert, U.B. Physical activity releases prostate-specific
antigen (PSA) from the prostate gland into blood and increases serum
PSA concentrations. Clin. Chem. 1996; 42: 691–5.
130. Leventhal, E.K., Rozanski, T.A., Morey, A.F. et al. The effects
of exercise and activity on serum prostate specific antigen levels.
J. Urol. 1993; 150: 893–4.
131. Piironen, T., Nurmi, M., Irjala, K. et al. Measurement of circulating
forms of prostate-specific antigen in whole blood immediately after
venipuncture: implications for point-of-care testing. Clin. Chem. 2001;
47: 703–11.
132. Tchetgen, M.B., Song, J.T., Strawderman, M. et al. Ejaculation
increases the serum prostate-specific antigen concentration. Urology
1996; 47: 511–6.
133. Crawford, E.D., Chia, D., Andriole, G. et al. PSA changes as related
to the initial PSA: data from the prostate, lung, colorectal and ovarian
cancer (PLCO) screening trial. Proc. Am. Soc. Clin. Oncol. 2001; 20:
177a.
134. Harris, C.H., Dalkin, B.L., Martin, E. et al. Prospective longitudinal
evaluation of men with initial prostate specific antigen levels of
4.0 ng/mL or less. J. Urol. 1997; 157: 1740–3.
135. Fowler, J.E., Jr., Bigler, S.A., Miles, D. et al. Predictors of
first repeat biopsy cancer detection with suspected local stage prostate
cancer. J. Urol. 2000; 163: 813–8.
136. Catalona, W.J., Partin, A.W., Finlay, J.A. et al. Use of percentage
of free prostate-specific antigen to identify men at high risk of prostate
cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination
is not suspicious for prostate cancer: an alternative model. Urology
1999; 54: 220–4.
137. Stephan, C., Jung, K., Cammann, H. et al. An artificial neural
network considerably improves the diagnostic power of percent free
prostate-specific antigen in prostate cancer diagnosis: results of
a 5-year investigation. Int. J. Cancer 2002; 99: 466–73.
138. Chen, Y.T., Luderer, A.A., Thiel, R.P. et al. Using proportions
of free to total prostate-specific antigen, age, and total prostate-specific
antigen to predict the probability of prostate cancer. Urology 1996;
47: 518–24.
139. Carter, H.B., Morrell, C.H., Pearson, J.D. et al. Estimation of
prostatic growth using serial prostate-specific antigen measurements
in men with and without prostate disease. Cancer Res. 1992; 52: 3323–8.
140. Lujan, M., Paez, A., Sanchez, E. et al. Prostate specific antigen
variation in patients without clinically evident prostate cancer. J.
Urol. 1999; 162: 1311–3.
141. Ciatto, S., Bonardi, R., Lombardi, C. et al. Analysis of PSA velocity
in 1666 healthy subjects undergoing total PSA determination at two
consecutive screening rounds. Int. J. Biol. Markers 2002; 17: 79–83.
142. Imai, K., Ichinose, Y., Kubota, Y. et al. Clinical significance
of prostate specific antigen for early stage prostate cancer detection.
Jpn. J. Clin. Oncol. 1994; 24: 160–5.
143. Larson, T.R., Robertson, D.W., Corica, A. et al. In vivo interstitial
temperature mapping of the human prostate during cryosurgery with correlation
to histopathologic outcomes. Urology 2000; 55: 547–52.
144. Goldstein, N.S., Kestin, L.L., Vicini, F.A. et al. The influence
of percentage of pre-radiation needle biopsies with adenocarcinoma
and total radiation dose on the pathologic response of unfavorable
prostate adenocarcinoma. Am. J. Clin. Pathol. 2002; 117: 927–34.
145. Lankford, S.P., Pollack, A., Zagars, G.K. Prostate-specific antigen
cancer volume: a significant prognostic factor in prostate cancer patients
at intermediate risk of failing radiotherapy. Int. J. Radiat. Oncol.
Biol. Phys. 1997; 38: 327–33.
146. Schulte, R.W., Slater, J.D., Rossi, C.J., Jr. et al. Value and
perspectives of proton radiation therapy for limited stage prostate
cancer. Strahlenther. Onkol. 2000; 176: 3–8.
147. Rossi, C.J., Jr., Slater, J.D., Reyes-Molyneux, N. et al. Particle
beam radiation therapy in prostate cancer: is there an advantage? Semin.
Radiat. Oncol. 1998; 8: 115–23.
148. Laramore, G.E., Krall, J.M., Thomas, F.J. et al. Fast neutron
radiotherapy for locally advanced prostate cancer: results of an RTOG
randomized study. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11: 1621–7.
149. Molls, M., Stadler, P., Becker, A. et al. Relevance of oxygen
in radiation oncology. Mechanisms of action, correlation to low hemoglobin
levels. Strahlenther. Onkol. 174(Suppl. 4): 13–6.
150. Stadler, P., Becker, A., Feldmann, H.J. et al. Influence of the
hypoxic subvolume on the survival of patients with head and neck cancer.
Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 749–54.
151. Dennis, L.K., Lynch, C.F., Torner, J.C. Epidemiologic association
between prostatitis and prostate cancer. Urology 2002; 60: 78–83.
152. Nelson, W.G., De Marzo, A.M., Deweese, T.L. et al. Preneoplastic
prostate lesions: an opportunity for prostate cancer prevention. Ann.
N.Y. Acad. Sci. 2001; 952: 135–44.
153. Orozco, R., O'Dowd, G., Kunnel, B. et al. Observations on pathology
trends in 62,537 prostate biopsies obtained from urology private practices
in the United States. Urology 1998; 51: 186–95.
154. Han, M., Snow, P.B., Epstein, J.I. et al. A neural network predicts
progression for men with Gleason score 3+4 versus 4+3 tumors after
radical prostatectomy. Urology 2000; 56: 994–9.
155. Sakr, W.A., Tefilli, M.V., Grignon, D.J. et al. Gleason score
7 prostate cancer: a heterogeneous entity? Correlation with pathologic
parameters and disease-free survival. Urology 2000; 56: 730–4.
156. Chan, T.Y., Partin, A.W., Walsh, P.C. et al. Prognostic significance
of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
Urology 2000; 56: 823–7.
157. Partin, A.W., Mangold, L.A., Lamm, D.M. et al. Contemporary update
of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology 2001; 58: 843–8.
158. D'Amico, A.V., Whittington, R., Malkowicz, S.B. et al. A multivariable
analysis of clinical factors predicting for pathological features associated
with local failure after radical prostatectomy for prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys. 194; 30: 293–302.
159. Carlson, G.D., Calvanese, C.B., Partin, A.W. An algorithm combining
age, total prostate-specific antigen (PSA), and percent free PSA to
predict prostate cancer: results on 4298 cases. Urology 1998; 52: 455–61.
160. Badalament, R.A., Miller, M.C., Peller, P.A. et al. An algorithm
for predicting nonorgan confined prostate cancer using the results
obtained from sextant core biopsies with prostate specific antigen
level. J. Urol. 1996; 156: 1375–80.
161. Partin, A.W., Kattan, M.W., Subong, E.N. et al. Combination of
prostate-specific antigen, clinical stage, and Gleason score to predict
pathological stage of localized prostate cancer. A multi-institutional
update. JAMA 1997; 277: 1445–51.
162. Kattan, M.W., Wheeler, T.M., Scardino, P.T. Postoperative nomogram
for disease recurrence after radical prostatectomy for prostate cancer.
J. Clin. Oncol. 1999; 17: 1499–1507.
163. Kattan, M.W., Zelefsky, M.J., Kupelian, P.A. et al. Pretreatment
nomogram for predicting the outcome of three-dimensional conformal
radiotherapy in prostate cancer. J. Clin. Oncol. 2000; 18: 3352–9.
164. Kattan, M.W., Potters, L., Blasko, J.C. et al. Pretreatment nomogram
for predicting freedom from recurrence after permanent prostate brachytherapy
in prostate cancer. Urology 2001; 58: 393–9.
165. Bluestein, D.L., Bostwick, D.G., Bergstralh, E.J. et al. Eliminating
the need for bilateral pelvic lymphadenectomy in select patients with
prostate cancer. J. Urol. 1994; 151: 1315–20.
166. Gilliland, F.D., Hoffman, R.M., Hamilton, A. et al. Predicting
extracapsular extension of prostate cancer in men treated with radical
prostatectomy: results from the population based prostate cancer outcomes
study. J. Urol. 1999; 162: 1341–5.
167. Lerner, S.E., Blute, M.L., Bergstralh, E.J. et al. Analysis of
risk factors for progression in patients with pathologically confined
prostate cancers after radical retropubic prostatectomy. J. Urol. 1996;
156: 137–43.
168. Pisansky, T.M., Kozelsky, T.F., Myers, R.P. et al. Radiotherapy
for isolated serum prostate specific antigen elevation after prostatectomy
for prostate cancer. J. Urol. 2000; 163: 845–50.
169. Gamito, E.J., Stone, N.N., Batuello, J.T. et al. Use of artificial
neural networks in the clinical staging of prostate cancer: implications
for prostate brachytherapy. Tech. Urol. 2000; 6: 60–3.
170. Stephan, C., Cammann, H., Semjonow, A. et al. Multicenter evaluation
of an artificial neural network to increase the prostate cancer detection
rate and reduce unnecessary biopsies. Clin. Chem. 2002; 48: 1279–87.
171. Ogawa, O., Egawa, S., Arai, Y. et al. Preoperative predictors
for organ-confined disease in Japanese patients with stage T1c prostate
cancer. Int. J. Urol. 1998; 5: 454–8.
172. Ziada, A.M., Lisle, T.C., Snow, P.B. et al. Impact of different
variables on the outcome of patients with clinically confined prostate
carcinoma: prediction of pathologic stage and biochemical failure using
an artificial neural network. Cancer 2001; 91: 1653–60.
173. Tewari, A., Porter, C., Peabody, J. et al. Predictive modeling
techniques in prostate cancer. Mol. Urol. 2001; 5: 147–52.
174. Errejon, A., Crawford, E.D., Dayhoff, J. et al. Use of artificial
neural networks in prostate cancer. Mol. Urol. 2001; 5: 153–8.
175. Porter, C., O'Donnell, C., Crawford, E.D. et al. Artificial neural
network model to predict biochemical failure after radical prostatectomy.
Mol. Urol. 2001; 5: 159–62.
176. Tewari, A., Issa, M., El-Galley, R. et al. Genetic adaptive neural
network to predict biochemical failure after radical prostatectomy:
a multi-institutional study. Mol. Urol. 2001; 5: 163–9.
177. Babaian, R.J., Fritsche, H., Ayala, A. et al. Performance of a
neural network in detecting prostate cancer in the prostate-specific
antigen reflex range of 2.5 to 4.0 ng/mL. Urology 2000; 56: 1000–6.
178. Blute, M.L., Bergstralh, E.J., Iocca, A. et al. Use of Gleason
score, prostate specific antigen, seminal vesicle and margin status
to predict biochemical failure after radical prostatectomy. J. Urol.
2001; 165: 119–25.
179. Conrad, S., Graefen, M., Pichlmeier, U. et al. Systematic sextant
biopsies improve preoperative prediction of pelvic lymph node metastases
in patients with clinically localized prostatic carcinoma. J. Urol.
1998; 159: 2023–9.
180. Batuello, J.T., Gamito, E.J., Crawford, E.D. et al. Artificial
neural network model for the assessment of lymph node spread in patients
with clinically localized prostate cancer. Urology 2001; 57: 481–5.
181. Long, J.P., Bahn, D., Lee, F. et al. Five-year retrospective,
multi-institutional pooled analysis of cancer-related outcomes after
cryosurgical ablation of the prostate. Urology 2001; 57: 518–23.
182. Critz, F.A., Williams, W.H., Levinson, A.K. et al. Simultaneous
irradiation for prostate cancer: intermediate results with modern techniques.
J. Urol. 2000; 164: 738–41; discussion, 741–3.
183. Blasko, J.C., Grimm, P.D., Sylvester, J.E. et al. Palladium-103
brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol.
Phys. 2000; 46: 839–50.
184. Onik, G. Cryosurgery. Crit. Rev. Oncol. Hematol. 1996; 23: 1–24.
185. Cohen, J.K., Miller, R.J., Rooker, G.M. et al. Cryosurgical ablation
of the prostate: two-year prostate-specific antigen and biopsy results.
Urology 1996; 47: 395–401.
186. Tatsutani, K., Rubinsky, B., Onik, G. et al. Effect of thermal
variables on frozen human primary prostatic adenocarcinoma cells. Urology
1996; 48: 441–7.
187. Lee, F., Bahn, D.K., McHugh, T.A. et al. Cryosurgery of prostate
cancer. Use of adjuvant hormonal therapy and temperature monitoring—a
one year follow-up. Anticancer Res. 1997; 17: 1511–5.
188. Ghafar, M.A., Johnson, C.W., De La Taille, A. et al. Salvage cryotherapy
using an argon based system for locally recurrent prostate cancer after
radiation therapy: the Columbia experience. J. Urol. 2001; 166: 1333–7;
discussion, 1337–8.
189. de la Taille, A., Benson, M.C., Bagiella, E. et al. Cryoablation
for clinically localized prostate cancer using an argon-based system:
complication rates and biochemical recurrence. BJU Int. 2000; 85: 281–6.
190. Onik, G. Image-guided prostate cryosurgery: state of the art.
Cancer Control 2001; 8: 522–31.
191. Zisman, A., Pantuck, A.J., Cohen, J.K. et al. Prostate cryoablation
using direct transperineal placement of ultrathin probes through a
17-gauge brachytherapy template-technique and preliminary results.
Urology 2001; 58: 988–93.
192. Dillioglugil, O., Leibman, B.D., Leibman, N.S. et al. Risk factors
for complications and morbidity after radical retropubic prostatectomy.
J. Urol. 1997; 157: 1760–7.
193. Albertsen, P.C., Fryback, D.G., Storer, B.E. et al. The impact
of co-morbidity on life expectancy among men with localized prostate
cancer. J. Urol. 1996; 156: 127–32.
194. Haban, P., Simoncic, R., Zidekova, E. et al. Role of fasting serum
C-peptide as a predictor of cardiovascular risk associated with the
metabolic X-syndrome. Med. Sci. Monit. 2002; 8: CR175–CR179.
195. Bhatti, M.S., Akbri, M.Z., Shakoor, M. Lipid profile in obesity.
J. Ayub Med. Coll. Abbottabad 2001; 13: 31–3.
196. Park, R., Detrano, R., Xiang, M. et al. Combined use of computed
tomography coronary calcium scores and C-reactive protein levels in
predicting cardiovascular events in nondiabetic individuals. Circulation
2002; 106: 2073–7.
197. Speidl, W.S., Graf, S., Hornykewycz, S. et al. High-sensitivity
C-reactive protein in the prediction of coronary events in patients
with premature coronary artery disease. Am. Heart J. 2002; 144: 449–55.
198. Albert, C.M., Ma, J., Rifai, N. et al. Prospective study of C-reactive
protein, homocysteine, and plasma lipid levels as predictors of sudden
cardiac death. Circulation 2002; 105: 2595–9.
199. Mayser, P., Mayer, K., Mahloudjian, M. et al. A double-blind,
randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based
lipid infusion in atopic dermatitis. J. Parenter. Enteral. Nutr. 2002;
26: 151–8.
200. Dewailly, E.E., Blanchet, C., Gingras, S. et al. Relations between
n-3 fatty acid status and cardiovascular disease risk factors among
Quebecers. Am. J. Clin. Nutr. 2001; 74: 603–11.
201. Watkins, B.A., Li, Y., Allen, K.G. et al. Dietary ratio of (n-6)/(n-3)
polyunsaturated fatty acids alters the fatty acid composition of bone
compartments and biomarkers of bone formation in rats. J. Nutr. 2000;
130: 2274–84.
202. Adams, P.B., Lawson, S., Sanigorski, A. et al. Arachidonic acid
to eicosapentaenoic acid ratio in blood correlates positively with
clinical symptoms of depression. Lipids 1996; 31(Suppl.): S157–S161.
203. Frost, R. Fire and Ice. In The Poetry of Robert Frost 1975, p.
220, Lathem, E.C., Ed. New York: Holt, Rinehart and Winston.
204. Barry, M.J., Fowler, F.J., Jr., O'Leary, M.P. et al. The American
Urological Association symptom index for benign prostatic hyperplasia.
The Measurement Committee of the American Urological Association. J.
Urol. 1992; 148: 1549–57; discussion, 1564.
205. Park, R., Martin, S., Goldberg, J.D. et al. Anastomotic strictures
following radical prostatectomy: insights into incidence, effectiveness
of intervention, effect on continence, and factors predisposing to
occurrence. Urology 2001; 57: 742–6.
206. Han, M., Piantadosi, S., Zahurak, M.L. et al. Serum acid phosphatase
level and biochemical recurrence following radical prostatectomy for
men with clinically localized prostate cancer. Urology 2001; 57: 707–11.
207. Webber, M.M., Waghray, A., Bello, D. Prostate-specific antigen,
a serine protease, facilitates human prostate cancer cell invasion.
Clin. Cancer Res. 1995; 1: 1089–94.
208. Kennedy-Smith, A.G., McKenzie, J.L., Owen, M.C. et al. Prostate
specific antigen inhibits immune responses in vitro: a potential role
in prostate cancer. J. Urol. 2002; 168: 741–7.
209. Lee, C., Sintich, S.M., Mathews, E.P. et al. Transforming growth
factor-beta in benign and malignant prostate. Prostate 1999; 39: 285–90.
210. Webber, M.M., Waghray, A. Urokinase-mediated extracellular matrix
degradation by human prostatic carcinoma cells and its inhibition by
retinoic acid. Clin. Cancer Res. 1995; 1: 755–61.
211. Shariat, S.F., Shalev, M., Menesses-Diaz, A. et al. Preoperative
plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly
predict progression in patients undergoing radical prostatectomy. J.
Clin. Oncol. 2001; 19: 2856–64.
212. Zelefsky, M.J., Lyass, O., Fuks, Z. et al. Predictors of improved
outcome for patients with localized prostate cancer treated with neoadjuvant
androgen ablation therapy and three-dimensional conformal radiotherapy.
J. Clin. Oncol. 1998; 16: 3380–5.
213. Strum, S.B., Scholz, M.C., McDermed, J.E. Intermittent androgen
deprivation in prostate cancer patients: factors predictive of prolonged
time off therapy. Oncologist 2000; 5: 45–52.
214. Szostak, M.J., Kaur, P., Amin, P. et al. Apoptosis and bcl-2 expression
in prostate cancer: significance in clinical outcome after brachytherapy.
J. Urol. 2001; 165: 2126–30.
215. Huang, A., Gandour-Edwards, R., Rosenthal, S.A. et al. p53 and
bcl-2 immunohistochemical alterations in prostate cancer treated with
radiation therapy. Urology 1998; 51: 346–51.
216. Scherr, D.S., Vaughan, E.D., Jr., Wei, J. et al. BCL-2 and p53
expression in clinically localized prostate cancer predicts response
to external beam radiotherapy. J. Urol. 1999; 162: 12–6; discussion,
16–7.
217. Rakozy, C., Grignon, D.J., Sarkar, F.H. et al. Expression of bcl-2,
p53, and p21 in benign and malignant prostatic tissue before and after
radiation therapy. Mod. Pathol. 1998; 11: 892–9.
218. Häggström, S., Lissbrant, I.F., Bergh, A. et al. Testosterone
induces vascular endothelial growth factor synthesis in the ventral
prostate in castrated rats. J. Urol. 1999; 161: 1620–5.
219. Cawley, H.M., Meltzer, S.J., De Benedetti, V.M. et al. Anti-p53
antibodies in patients with Barrett's esophagus or esophageal carcinoma
can predate cancer diagnosis. Gastroenterology 1998; 115: 19–27.
220. Smith, C.A., Pollice, A.A., Gu, L.P. et al. Correlations among
p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter
flow cytometry in human breast cancer: evidence for a common phenotypic
evolutionary pattern in infiltrating ductal carcinomas. Clin. Cancer
Res. 2000; 6: 112–26.
221. Hughes-Fulford, M., Chen, Y., Tjandrawinata, R.R. Fatty acid regulates
gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis
2001; 22: 701–7.
222. Rose, D.P. Dietary fatty acids and prevention of hormone-responsive
cancer. Proc. Soc. Exp. Biol. Med. 1997; 216: 224–33.
223. North, G.L. Celecoxib as adjunctive therapy for treatment of colorectal
cancer. Ann. Pharmacother. 2001; 35: 1638–43.
224. Zhao, J., Sharma, Y., Agarwal, R. Significant inhibition by the
flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused
modulation of antioxidant and inflammatory enzymes, and cyclooxygenase
2 and interleukin-1alpha expression in SENCAR mouse epidermis: implications
in the prevention of stage I tumor promotion. Mol. Carcinog. 1999;
26: 321–33.
225. Kelavkar, U.P., Cohen, C., Kamitani, H. et al. Concordant induction
of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma:
correlation with Gleason staging. Carcinogenesis 2000; 21: 1777–87.
226. Stojdl, D.F., Lichty, B., Knowles, S. et al. Exploiting tumor-specific
defects in the interferon pathway with a previously unknown oncolytic
virus. Nat. Med. 2000; 6: 821–5.
227. Balachandran, S., Barber, G.N. Vesicular stomatitis virus (VSV)
therapy of tumors. IUBMB Life 2000; 50: 135–8.
228. Balachandran, S., Porosnicu, M., Barber, G.N. Oncolytic activity
of vesicular stomatitis virus is effective against tumors exhibiting
aberrant p53, ras, or myc function and involves the induction of apoptosis.
J. Virol. 2001; 75: 3474–9.
229. Rajan, P., Swaminathan, S., Zhu, J. et al. A novel translational
regulation function for the simian virus 40 large-T antigen gene. J.
Virol. 1995; 69: 785–95.
230. Randazzo, B.P., Tal-Singer, R., Zabolotny, J.M. et al. Herpes
simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate
in CV-1 cells due to a translational block that can be overcome by
coinfection with SV40. J. Gen. Virol. 1997; 78: 3333–9.
231. Reid, T.M., Loeb, L.A. Mutagenic specificity of oxygen radicals
produced by human leukemia cells. Cancer Res. 1992; 52: 1082–6.
232. Macmillan-Crow, L.A., Cruthirds, D.L. Invited review: manganese
superoxide dismutase in disease. Free Radic. Res. 2001; 34: 325–36.
233. Sigala, S., Tognazzi, N., Rizzetti, M.C. et al. Nerve growth factor
induces the re-expression of functional androgen receptors and p75(NGFR)
in the androgen-insensitive prostate cancer cell line DU145. Eur. J.
Endocrinol. 2002; 147: 407–15.
234. Wouters, B.G., Weppler, S.A., Koritzinsky, M. et al. Hypoxia as
a target for combined modality treatments. Eur. J. Cancer 2002; 38:
240–57.
235. Leith, J.T., Cook, S., Chougule, P. et al. Intrinsic and extrinsic
characteristics of human tumors relevant to radiosurgery: comparative
cellular radiosensitivity and hypoxic percentages. Acta Neurochir.
Suppl. 1994; 62: 18–27.
236. Dachs, G.U., Dougherty, G.J., Stratford, I.J. et al. Targeting
gene therapy to cancer: a review. Oncol. Res. 1997; 9: 313–25.
237. Fosslien, E. Review: molecular pathology of cyclooxygenase-2 in
cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 2001; 31: 325–48.
238. Liu, X.H., Kirschenbaum, A., Yao, S. et al. Inhibition of cyclooxygenase-2
suppresses angiogenesis and the growth of prostate cancer in vivo.
J. Urol. 2000; 164: 820–5.
239. Stewart, R.J., Panigrahy, D., Flynn, E. et al. Vascular endothelial
growth factor expression and tumor angiogenesis are regulated by androgens
in hormone responsive human prostate carcinoma: evidence for androgen
dependent destabilization of vascular endothelial growth factor transcripts.
J. Urol. 2001; 165: 688–93.
240. Levine, A.C., Liu, X.H., Greenberg, P.D. et al. Androgens induce
the expression of vascular endothelial growth factor in human fetal
prostatic fibroblasts. Endocrinology 1998; 139: 4672–8.
241. Keledjian, K., Borkowski, A., Kim, G. et al. Reduction of human
prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Prostate 2001; 48: 71–8.
242. Joseph, I.B., Isaacs, J.T. Macrophage role in the anti-prostate
cancer response to one class of antiangiogenic agents. J. Natl. Cancer
Inst. 1998; 90: 1648–53.
243. Joseph, I.B., Vukanovic, J., Isaacs, J.T. Antiangiogenic treatment
with linomide as chemoprevention for prostate, seminal vesicle, and
breast carcinogenesis in rodents. Cancer Res. 1996; 56: 3404–8.
244. Khalil, A., Tullus, K., Bakhiet, M. et al. Angiotensin II type
1 receptor antagonist (losartan) down-regulates transforming growth
factor-beta in experimental acute pyelonephritis. J. Urol. 2000; 164:
186–91.
245. Selzer, M.G., Zhu, B., Block, N.L. et al. CMT-3, a chemically
modified tetracycline, inhibits bony metastases and delays the development
of paraplegia in a rat model of prostate cancer. Ann. N.Y. Acad. Sci.
1999; 878: 678–82.
246. Lokeshwar, B.L., Selzer, M.G., Zhu, B.Q. et al. Inhibition of
cell proliferation, invasion, tumor growth and metastasis by an oral
non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate
cancer model. Int. J. Cancer 2002; 98: 297–309.
247. Paget, S. Distribution of secondary growths in cancer of the breast.
Lancet 1989; 1: 571–3.
248. Smith, M.R., McGovern, F.J., Fallon, M.A. et al. Low bone mineral
density in hormone-naive men with prostate carcinoma. Cancer 2001;
91: 2238–45.
249. Strum, S.B., Scholz, M.C. Quantitative computerized tomography
in prostate cancer. J. Urol. 2003 (submitted).
250. Bolotin, H.H. Inaccuracies inherent in dual-energy X-ray absorptiometry
in vivo bone mineral densitometry may flaw osteopenic/osteoporotic
interpretations and mislead assessment of antiresorptive therapy effectiveness.
Bone 2001; 28: 548–55.
251. Frahm, C., Link, J., Hakelberg, K. et al. Densitometry in suspected
preclinical osteoporosis: quantitative computerized tomography versus
dual energy roentgen absorptiometry. Bildgebung 1994; 61: 256–62.
252. von Stremple, A., Prokopp, M., Flindt, C. A comparison of two
noninvasive measurement methods for determining central osteoporosis
taking into consideration the ash content. Aktuelle Radiol. 1993; 3:
31–6.
253. Meirelles, E.S., Borelli, A., Camargo, O.P. Influence of disease
activity and chronicity on ankylosing spondylitis bone mass loss. Clin.
Rheumatol. 1999; 18: 364–8.
254. von der Recke, P., Hansen, M.A., Overgaard, K. et al. The impact
of degenerative conditions in the spine on bone mineral density and
fracture risk prediction. Osteoporos. Int. 1996; 6: 43–9.
255. Tremollieres, F., Pouilles, J.M., Ribot, C. Screening techniques.
Presse Med. 2002; 31: 694–8.
256. Trivedi, D.P., Khaw, K.T. Bone mineral density at the hip predicts
mortality in elderly men. Osteoporos. Int. 2001; 12: 259–65.
257. Thorsen, K., Nordstrom, P., Lorentzon, R. et al. The relation
between bone mineral density, insulin-like growth factor I, lipoprotein
(a), body composition, and muscle strength in adolescent males. J.
Clin. Endocrinol. Metab. 1999; 84: 3025–9.
258. Prie, D., Huart, V., Bakouh, N. et al. Nephrolithiasis and osteoporosis
associated with hypophosphatemia caused by mutations in the type 2a
sodium-phosphate cotransporter. N. Engl. J. Med. 2002; 347: 983–91.
259. Pak, C.Y., Peterson, R.D., Poindexter, J. Prevention of spinal
bone loss by potassium citrate in cases of calcium urolithiasis. J.
Urol. 2002; 168: 31–4.
260. Yasui, T., Fujita, K., Sasaki, S. et al. Alendronate inhibits
osteopontin expression enhanced by parathyroid hormone-related peptide
(PTHrP) in the rat kidney. Urol. Res. 1998; 26: 355–60.
261. Cappuccio, F.P., Kalaitzidis, R., Duneclift, S. et al. Unraveling
the links between calcium excretion, salt intake, hypertension, kidney
stones and bone metabolism. J. Nephrol. 2000; 13: 169–77.
262. Siegall, C.B., Schwab, G., Nordan, R.P. et al. Expression of the
interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Cancer Res. 1990; 50: 7786–8.
263. Borsellino, N., Belldegrun, A., Bonavida, B. Endogenous interleukin
6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated
cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995;
55: 4633–9.
264. Wise, G.J., Marella, V.K., Talluri, G. et al. Cytokine variations
in patients with hormone treated prostate cancer. J. Urol. 2000; 164:
722–5.
265. Garcia-Moreno, C., Mendez-Davila, C., de La Piedra, C. et al.
Human prostatic carcinoma cells produce an increase in the synthesis
of interleukin-6 by human osteoblasts. Prostate 2002; 50: 241–6.
266. Liu, X.H., Kirschenbaum, A., Lu, M. et al. Prostaglandin E(2)
stimulates prostatic intraepithelial neoplasia cell growth through
activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem.
Biophys. Res. Commun. 2002; 290: 249–55.
267. Spiotto, M.T., Chung, T.D. STAT3 mediates IL-6-induced neuroendocrine
differentiation in prostate cancer cells. Prostate 2000; 42: 186–95.
268. Coukell, A.J., Markham, A. Pamidronate. A review of its use in
the management of osteolytic bone metastases, tumour-induced hypercalcaemia
and Paget's disease of bone. Drugs Aging 1998; 12: 149–68.
269. Blumsohn, A., Herrington, K., Hannon, R.A. et al. The effect of
calcium supplementation on the circadian rhythm of bone resorption.
J. Clin. Endocrinol. Metab. 1994; 79: 730–5.
270. Gross, C., Stamey, T., Hancock, S. et al. Treatment of early recurrent
prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol.
1998; 159: 2035–9; discussion, 2039–40.
271. Beer, T.M., Munar, M., Henner, W.D. A Phase I trial of pulse calcitriol
in patients with refractory malignancies: pulse dosing permits substantial
dose escalation. Cancer 2001; 91: 2431–9.
272. Beer, T.M., Filers, K.M., Garzotto, M. et al. Androgen-independent
prostate cancer (AIPC) treatment with weekly high-dose calcitriol and
docetaxel. Proc. Am. Soc. Clin. Oncol. 2002; 21: 177a.
273. Nijs, H.G., Essink-Bot, M.L., DeKoning, H.J. et al. Why do men
refuse to attend population-based screening for prostate cancer? J.
Public Health Med. 2000; 22: 312–6.
274. Webb, J.A., Shanmuganathan, K., McLean, A. Complications of ultrasound-guided
transperineal prostate biopsy. A prospective study. Br. J. Urol. 1993;
72: 775–7.
275. Lujan Galan, M., Paez Borda, A., Fernandez Gonzalez, I. et al.
Adverse effects of transrectal prostatic biopsy. Analysis of 303 procedures.
Actas Urol. Esp. 2001; 25: 46–9.
276. Kearney, M.C., Bingham, J.B., Bergland, R. et al. Clinical predictors
in the use of finasteride for control of gross hematuria due to benign
prostatic hyperplasia. J. Urol. 2002; 167: 2489–91.
277. Sordello, S., Bertrand, N., Plouet, J. Vascular endothelial growth
factor is up-regulated in vitro and in vivo by androgens. Biochem.
Biophys. Res. Commun. 1998; 251: 287–90.
278. Haggstrom, S., Torring, N., Moller, K. et al. Effects of finasteride
on vascular endothelial growth factor. Scand. J. Urol. Nephrol. 2002;
36: 182–7.
279. Costa, C., Soares, R., Reis-Filho, J.S. et al. Cyclo-oxygenase
2 expression is associated with angiogenesis and lymph node metastasis
in human breast cancer. J. Clin. Pathol. 2002; 55: 429–34.
280. Kaji, Y., Kurhanewicz, J., Hricak, H. et al. Localizing prostate
cancer in the presence of postbiopsy changes on MR images: role of
proton MR spectroscopic imaging. Radiology 1998; 206: 785–90.
281. Davis, M., Sofer, M., Kim, S.S. et al. The procedure of transrectal
ultrasound guided biopsy of the prostate: a survey of patient preparation
and biopsy technique. J. Urol. 2002; 167: 566–70.
282. Shandera, K.C., Thibault, G.P., Deshon, G.E., Jr. Efficacy of
one dose fluoroquinolone before prostate biopsy. Urology 1998; 52:
641–3.
283. Aron, M., Rajeev, T.P., Gupta, N.P. Antibiotic prophylaxis for
transrectal needle biopsy of the prostate: a randomized controlled
study. BJU Int. 2000; 85: 682–5.
284. Pareek, G., Armenakas, N.A., Fracchia, J.A. Periprostatic nerve
blockade for transrectal ultrasound guided biopsy of the prostate:
a randomized, double-blind, placebo controlled study. J. Urol. 2001;
166: 894–7.
285. Nash, P.A., Bruce, J.E., Indudhara, R. et al. Transrectal ultrasound
guided prostatic nerve blockade eases systematic needle biopsy of the
prostate. J. Urol. 1996; 155: 607–9.
286. Lynn, N.N., Collins, G.N., Brown, S.C. et al. Periprostatic nerve
block gives better analgesia for prostatic biopsy. BJU Int. 2002; 90:
424–6.
287. Soloway, M.S., Obek, C. Periprostatic local anesthesia before
ultrasound guided prostate biopsy. J. Urol. 2000; 163: 172–3.
288. Alavi, A.S., Soloway, M.S., Vaidya, A. et al. Local anesthesia
for ultrasound guided prostate biopsy: a prospective randomized trial
comparing 2 methods. J. Urol. 2001; 166: 1343–5.
289. Saad, F., Sabbagh, R., McCormack, M. et al. A prospective randomized
trial comparing lidocaine and lubrificating gel on pain level in patients
undergoing transrectal ultrasound prostate biopsy. Can. J. Urol. 2002;
9: 1592–4.
290. Issa, M.M., Bux, S., Chun, T. et al. A randomized prospective
trial of intrarectal lidocaine for pain control during transrectal
prostate biopsy: the Emory University experience. J. Urol. 2002; 164:
397–9.
291. Masood, J., Shah, N., Lane, T. et al. Nitrous oxide (Entonox)
inhalation and tolerance of transrectal ultrasound guided prostate
biopsy: a double-blind randomized controlled study. J. Urol. 2002;
168: 116–20;
discussion, 120.
292. Irani, J., Fournier, F., Bon, D. et al. Patient tolerance of transrectal
ultrasound-guided biopsy of the prostate. Br. J. Urol. 1997; 79: 608–10.
293. Monti, S., Sciarra, F., Adamo, M.V. et al. Prevalent decrease
of the EGF content in the periurethral zone of BPH tissue induced by
treatment with finasteride or flutamide. J. Androl. 1997; 18: 488–94.
294. Laroque, P.A., Prahalada, S., Molon-Noblot, S. et al. Quantitative
evaluation of glandular and stromal compartments in hyperplastic dog
prostates: effect of 5-alpha reductase inhibitors. Prostate 1995; 27:
121–8.
295. Saez, C., Gonzalez-Baena, A.C., Japon, M.A. et al. Expression
of basic fibroblast growth factor and its receptors FGFR1 and FGFR2
in human benign prostatic hyperplasia treated with finasteride. Prostate
1999; 40: 83–8.
296. Wang, L.G., Liu, X.M., Kreis, W. et al. Down-regulation of prostate-specific
antigen expression by finasteride through inhibition of complex formation
between androgen receptor and steroid receptor-binding consensus in
the promoter of the PSA gene in LNCaP cells. Cancer Res. 1997; 57:
714–9.
297. Glassman, D.T., Chon, J.K., Borkowski, A. et al. Combined effect
of terazosin and finasteride on apoptosis, cell proliferation, and
transforming growth factor-beta expression in benign prostatic hyperplasia.
Prostate 2001; 46: 45–51.
298. Ng, Y.K., Bales, W., Box, E. et al. Cardura induced apoptosis
in prostate cancer cells in vitro. Proc. Annu. Meet. Am. Assoc. Cancer
Res. 1997; 38: A615.
299. Chon, J.K., Borkowski, A., Partin, A.W. et al. Alpha 1-adrenoceptor
antagonists terazosin and doxazosin induce prostate apoptosis without
affecting cell proliferation in patients with benign prostatic hyperplasia.
J. Urol. 1999; 161: 2002–8.
300. Benning, C.M., Kyprianou, N. Quinazoline-derived alpha1-adrenoceptor
antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent
action. Cancer Res. 2002; 62: 597–602.
301. Kyprianou, N., Benning, C.M. Suppression of human prostate cancer
cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin
via induction of apoptosis. Cancer Res. 2000; 60: 4550–5.
302. Cuellar, D.C., Rhee, J., Kyprianou, N. Alpha1-adrenoceptor antagonists
radiosensitize prostate cancer cells via apoptosis induction. Anticancer
Res. 2002; 22: 1673–9.
303. Huncharek, M., Muscat, J. Serum prostate-specific antigen as a
predictor of staging abdominal/pelvic computed tomography in newly
diagnosed prostate cancer. Abdom. Imaging 1996; 21: 364–7.
304. Huncharek, M., Muscat, J. Serum prostate-specific antigen as a
predictor of radiographic staging studies in newly diagnosed prostate
cancer. Cancer Invest. 1995; 13: 31–5.
305. Chybowski, F.M., Keller, J.J., Bergstralh, E.J. et al. Predicting
radionuclide bone scan findings in patients with newly diagnosed, untreated
prostate cancer: prostate specific antigen is superior to all other
clinical parameters. J. Urol. 1991; 145: 313–8.
306. Oesterling, J.E., Martin, S.K., Bergstralh, E.J. et al. The use
of prostate-specific antigen in staging patients with newly diagnosed
prostate cancer. JAMA 1993; 269: 57–60.
307. Sciarra, F., Sorcini, G., Di Silverio, F. et al. Plasma testosterone
and androstenedione after orchiectomy in prostatic adenocarcinoma.
Clin. Endocrinol. 1973; 2: 101–9.
308. Gibson, C.H. A concept analysis of empowerment. J. Adv. Nurs.
1991; 16: 354–61.
309. Davison, B.J., Degner, L.F. Empowerment of men newly diagnosed
with prostate cancer. Cancer Nurs. 1997; 20: 187–96.
310. Jones, P.S., Meleis, A.I. Health is empowerment. Adv Nurs. Sci.
1993; 15: 1–14. |